Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present in approximately 30% of patients with non-small cell lung cancer.
|
31454018 |
2019 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report.
|
31250402 |
2019 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF inhibition has demonstrated anti-tumor activity in patients with BRAF V600E mutant NSCLC.
|
30019008 |
2018 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the present review, we propose an overview of the available evidence about BRAF in NSCLC mutations (V600E and non-V600E), from biological significance to emerging clinical implications of BRAF mutations detection.
|
29729495 |
2018 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among 2690 patients with genotyped NSCLC during the study period, BRAF mutations were identified in 80 (3%) cases, consisting of V600E substitution in 42 (53%) cases; non-V600E mutation were observed in 38 (48%) cases.
|
26711930 |
2016 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
|
27196768 |
2016 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method.
|
24552757 |
2014 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations were identified in 140 (55.8%) NSCLC patients (118 in adenocarcinoma, 11 in squamous cell carcinoma, 7 in adenocarcinoma and 4 in NSCLC-not otherwise specified), including four novel substitutions (L718M, A743V, L815P, V819E).
|
24040454 |
2013 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
IHC using the VE1 clone is a specific and sensitive method for the detection of BRAF(V600E) and may be an alternative to molecular biology for the detection of mutations in NSCLC.
|
23131393 |
2013 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
Non-Small Cell Lung Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We report for the first time to our knowledge that V600E and non-V600E BRAF mutations affect different patients with NSCLC.
|
21825258 |
2011 |